Important information on Gliolan (5-aminolevulinic acid, 5-ALA): What to do in case of delayed surgery and information on fluorescence in non high-grade glioma
About
This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.
Documents
Key facts
Medicine name |
Gliolan
|
Active substance |
5-aminolevulinic acid hydrochloride
|
Therapeutic area (MeSH) |
Glioma
|
Procedure number |
EMEA/H/C/000744/II/0018/G
|
Regulatory outcome |
Variation
|
DHPC type |
Type II variation
|
Referral name |
Cyproterone-containing medicinal products
|
Human ATC code |
L01XD04
|
Dissemination date |
01/12/2020
|